NXGLHIGH SIGNALFINANCIAL10-K

NXGL experienced a dramatic 41,619% increase in cash position to $13.3M while significantly reducing interest expense by 98.9%, indicating a major capital infusion or debt restructuring event.

The massive cash increase combined with near-elimination of interest expense suggests NXGL either raised substantial capital or restructured/paid down significant debt, fundamentally altering its financial position. This transformation provides the company with substantially improved liquidity and reduced financial risk, though the 22.5% decline in stockholders' equity may indicate dilution from equity financing.

Comparing 2026-03-31 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

NXGL showed strong operational improvements with revenue growing 31.5% to $11.4M and gross profit surging 64.1% to $4.5M, demonstrating improving business fundamentals. The company dramatically strengthened its balance sheet with cash skyrocketing over 41,000% to $13.3M while slashing interest expense by 98.9%, though stockholders' equity declined 22.5% suggesting potential dilution. Operating cash flow improved significantly from -$3.9M to -$1.3M, and the company substantially reduced capital expenditures and R&D spending, indicating either improved efficiency or potential underinvestment in growth.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+41618.8%
$32K$13.3M

Cash position surged 41618.8% — strong cash generation or capital raise providing significant financial cushion.

Interest Expense
P&L
-98.9%
$1.3M$15K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

R&D Expense
P&L
-97.4%
$78K$2K

R&D spending cut 97.4% — could signal cost discipline or concerning reduction in innovation investment.

Capital Expenditure
Cash Flow
-84.7%
$443K$68K

Capex reduced 84.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
+66.1%
-$3.9M-$1.3M

Operating cash flow surged 66.1% — exceptional cash generation, highest quality earnings signal.

Gross Profit
P&L
+64.1%
$2.7M$4.5M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Revenue
P&L
+31.5%
$8.7M$11.4M

Strong top-line growth of 31.5% — accelerating demand or successful expansion into new markets.

Accounts Receivable
Balance Sheet
-27.9%
$933K$673K

Receivables declined — improved collection efficiency or conservative revenue recognition.

SG&A Expense
P&L
+26.3%
$6.2M$7.9M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Stockholders Equity
Balance Sheet
-22.5%
$5.8M$4.5M

Equity decreased 22.5% — buybacks or losses reducing book value, monitor solvency ratios.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-27
ADDED
As of March 31, 2026 the registrant had 8,475,693 shares of common stock outstanding.
We distribute our products as a contract manufacturer, supplying our gels to third parties who incorporate them into their own products.
We also have a line of branded consumer products sold direct to consumers and custom and white label opportunities, which focuses on combining our gels with proprietary branded products and white label opportunities.
Contract Manufacturing Business As described above, we serve as a contract manufacturer, supplying our gels to third parties who incorporate them into their own products.
Consumer Products Our branded consumer products are marketed under a diverse portfolio of brands, including our Medagel family of products (SilverSeal, Hexagels, Turfguard), Kenkoderm, and Silly George.
+7 more — sign up free →
REMOVED
As of March 27, 2025, the registrant had 7,654,037 shares of common stock outstanding.
We have historically served as a contract manufacturer, supplying our gels to third parties who incorporate them into their own products.
Contract Manufacturing Business As described above, we have historically served as a contract manufacturer, supplying our gels to third parties who incorporate them into their own products.
Consumer Products Beginning in the third quarter of 2020, we began selling our own branded products using our hydrogel technology on the Amazon marketplace.
In 2022 we expanded access to our products by launching our own direct to consumer website, Medagel.com.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →